REFERENCES
- Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc R Soc Lond Ser B Biol Sci 1957; B147: 258–67.
- Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–64.
- Leonard WJ, Oshea JJ. JAKS and STATs: biological implications. Annu Rev Immunol 1998; 16: 293–322.
- Linzer DIH, Levine AJ. Characterization of a 54 K Dalton cellular 5V40 tumor antigen present in 51/40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43–52.
- Oren M, Levine AJ. Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen. Proc Natl Acad Sci 1983; 80: 56–9.
- Vousden KH, Lu X. Live or let die: the cell's response to p53. Nature Rev Cancer 2002; 2: 594— 604.
- Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Cliff Opin Genet Dev 1996; 6: 12 — 8.
- Okomato K, Beach D. Cyclin G is a transcrip-tional target of the p53 tumor suppressor protein. EMBO J 1994; 13: 4816–22.
- Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Lieberman DA, Hoffman B, Reed JC. Tumor suppressor p53 is a regulator of bc1-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799–805.
- Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461–8.
- Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701 — 4.
- Deng C, Zang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21 Cip/wafl undergo normal development but are defective in G1 checkpoint control. Cell 1995; 82: 675–84.
- El-Diery WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–25.
- Mendelshon J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 1997; 89: 341–3.
- Chow NH, Liu HS, Lee El, Chang CJ, Chan SH, Cheng HL, Tzai TS, Lin JS. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17: 1293–6.
- Fischer CJ, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and out-come of patients. Anticancer Res 1997; 17: 613–9.
- Price JT, Wilson HM, Haites NE. Epidermal growth factor increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur J Cancer 1996; 32A: 1977–82.
- Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-ErbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibro-blasts. FEBS Lett 1998; 425: 145–50.
- Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon conl with natural recombinant interferons-a: antiviral, antipro-liferative, and natural killer-inducing activities. J Interferon Res 1992; 12: 55–9.
- Dillman RO, Shea WM, Tai DF, Mahdavi K, Bart NM, Kharkar BR, Poor MM, Church CK, DePriest C. Interferon-alpha 2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-oncol 2001; 3: 35–41.
- Niemela M, Maenpaa H, Salven P, Summanen P, Poussa K, Laatikainen L, Jaaskelainen J, Joensuu H. Interferon alpha-2a therapy in 18 hemangio-blastomas. Clin Cancer Res 2001; 7: 510–6.